X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4083) 4083
Publication (301) 301
Book Review (51) 51
Conference Proceeding (6) 6
Book / eBook (4) 4
Book Chapter (4) 4
Magazine Article (4) 4
Data Set (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2891) 2891
male (2206) 2206
animals (1830) 1830
piperidines - pharmacokinetics (1818) 1818
index medicus (1663) 1663
piperidines - pharmacology (1512) 1512
female (1443) 1443
pharmacology & pharmacy (1211) 1211
adult (1093) 1093
piperidines - administration & dosage (1071) 1071
pharmacokinetics (1031) 1031
rats (988) 988
middle aged (855) 855
piperidines - therapeutic use (850) 850
piperidines - adverse effects (643) 643
aged (590) 590
dose-response relationship, drug (586) 586
mice (551) 551
anesthesiology (535) 535
remifentanil (526) 526
piperidines - chemistry (506) 506
piperidines - blood (476) 476
administration, oral (461) 461
chemistry, medicinal (409) 409
pharmacodynamics (350) 350
rats, sprague-dawley (338) 338
piperidines - metabolism (330) 330
double-blind method (327) 327
drug interactions (326) 326
structure-activity relationship (310) 310
neurosciences (291) 291
piperidines - chemical synthesis (291) 291
brain - metabolism (288) 288
time factors (287) 287
anesthesia (272) 272
tissue distribution (267) 267
treatment outcome (265) 265
propofol (262) 262
dogs (248) 248
adolescent (243) 243
biological availability (233) 233
half-life (230) 230
young adult (222) 222
double-blind (218) 218
area under curve (212) 212
rats, wistar (209) 209
research (209) 209
analysis (208) 208
kinetics (206) 206
alfentanil (199) 199
surgery (199) 199
chemistry, organic (195) 195
oncology (193) 193
anesthetics, intravenous - administration & dosage (189) 189
piperidines (188) 188
pharmacology (184) 184
biochemistry & molecular biology (182) 182
efficacy (179) 179
metabolism (176) 176
infusions, intravenous (175) 175
psychiatry (175) 175
fentanyl (173) 173
analgesics, opioid - administration & dosage (170) 170
propofol - administration & dosage (165) 165
heart rate - drug effects (164) 164
blood pressure - drug effects (163) 163
drug therapy (163) 163
in-vitro (163) 163
cross-over studies (162) 162
cancer (161) 161
donepezil (161) 161
pharmacology/toxicology (161) 161
medicine & public health (155) 155
in vitro techniques (153) 153
brain (152) 152
chromatography, high pressure liquid (150) 150
molecular structure (150) 150
aged, 80 and over (143) 143
models, biological (143) 143
prospective studies (143) 143
alzheimer's disease (142) 142
alzheimers-disease (139) 139
reproducibility of results (139) 139
drug administration schedule (138) 138
brain - drug effects (134) 134
injections, intravenous (134) 134
alzheimer disease - drug therapy (133) 133
disease models, animal (132) 132
carbamates - pharmacokinetics (130) 130
clinical neurology (130) 130
clinical trials as topic (130) 130
ligands (129) 129
safety (129) 129
toxicology (129) 129
article (128) 128
dosage and administration (128) 128
research article (128) 128
drugs (127) 127
indans - pharmacokinetics (127) 127
brain - diagnostic imaging (126) 126
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3960) 3960
German (39) 39
Japanese (20) 20
French (19) 19
Spanish (16) 16
Chinese (14) 14
Russian (5) 5
Polish (4) 4
Turkish (4) 4
Danish (2) 2
Hungarian (2) 2
Italian (2) 2
Norwegian (2) 2
Portuguese (2) 2
Bulgarian (1) 1
Dutch (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2010, Volume 333, Issue 3, pp. 788 - 796
Journal Article
ANAESTHESIA AND INTENSIVE CARE, ISSN 0310-057X, 06/2005, Volume 33, Issue 3, pp. 311 - 322
The clinical utility of most analgesic drugs is altered in the presence of patients with impaired renal or hepatic function not simply because of altered... 
acute pain | MORPHINE | ORTHOTOPIC LIVER-TRANSPLANTATION | CONTROLLED ANALGESIA | hepatic function | VALPROATE | CARBAMAZEPINE | FAILURE | DISPOSITION | PLASMA | PHARMACOKINETICS | hepatic failure | review | renal function | ANESTHESIOLOGY | REMIFENTANIL | analgesia : renal failure | CRITICAL CARE MEDICINE | Kidney Failure, Chronic - physiopathology | Analgesics - therapeutic use | Pain - drug therapy | Humans | Half-Life | Biological Availability | Metabolic Clearance Rate | Analgesics - pharmacokinetics | Liver Diseases - physiopathology | Liver Diseases - metabolism | Contraindications | Kidney Failure, Chronic - metabolism | Methadone, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Piperidines, pharmacokinetics | Hydrocodone, pharmacokinetics | Fentanyl, pharmacokinetics | Pain, complications | Buprenorphine, pharmacokinetics | Hydrocodone, administration and dosage | Carbamazepine, pharmacokinetics | Acute Disease | Ketamine, pharmacokinetics | Sufentanil, pharmacokinetics | Propoxyphene, pharmacokinetics | Acetaminophen, adverse effects | Clonidine, administration and dosage | Morphine, administration and dosage | Oxycodone, administration and dosage | Propoxyphene, administration and dosage | Hydromorphone, administration and dosage | Methadone, administration and dosage | Alfentanil, pharmacokinetics | Buprenorphine, administration and dosage | Codeine, pharmacokinetics | Meperidine, pharmacokinetics | Sufentanil, administration and dosage | Anesthetics, Local, therapeutic use | Codeine, administration and dosage | Mexiletine, pharmacokinetics | Mexiletine, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, therapeutic use | Liver Failure, complications | Alfentanil, administration and dosage | Piperidines, administration and dosage | Pain, drug therapy | Ketamine, administration and dosage | Fentanyl, administration and dosage | Carbamazepine, administration and dosage | Hydromorphone, pharmacokinetics | Ketorolac, pharmacokinetics | Analgesics, Opioid, therapeutic use | Ketorolac, administration and dosage | Tramadol, administration and dosage | Morphine, pharmacokinetics | Valproic Acid, pharmacokinetics | Acetaminophen, administration and dosage | Valproic Acid, administration and dosage | Tramadol, pharmacokinetics | Acetic Acids | Kidney Failure, complications | Antidepressive Agents, Tricyclic, therapeutic use | Meperidine, administration and dosage | Clonidine, pharmacokinetics | Analgesics, Non-Narcotic, therapeutic use | Oxycodone, pharmacokinetics | Valproic Acid, adverse effects | Analgesia: renal failure, renal function, hepatic failure, hepatic function, review | Acute pain
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 11/2017, Volume 109, pp. 21 - 30
The lipophilic phytocannabinoids cannabidiol (CBD) and Δ -tetrahydrocannabinol (THC) show therapeutic efficacy in various medical conditions. Both molecules... 
Cannabinoids | Oral bioavailability | Piperine | SNEDDS | First pass effect | RESVERATROL | CURCUMIN | P-GLYCOPROTEIN | UDP-GLUCURONOSYLTRANSFERASE | IN-VITRO | LIPID-BASED FORMULATIONS | METABOLISM | PHARMACOKINETICS | ENZYMES | PHARMACOLOGY & PHARMACY | Polyunsaturated Alkamides - chemistry | Emulsions | Stilbenes - administration & dosage | Cannabidiol - administration & dosage | Excipients - pharmacokinetics | Nanoparticles - chemistry | Rats, Wistar | Alkaloids - pharmacokinetics | Curcumin - chemistry | Biological Availability | Male | Stilbenes - chemistry | Benzodioxoles - administration & dosage | Curcumin - administration & dosage | Drug Delivery Systems | Lipids - chemistry | Excipients - chemistry | Benzodioxoles - pharmacokinetics | Piperidines - pharmacokinetics | Benzodioxoles - chemistry | Cannabidiol - pharmacokinetics | Cannabidiol - chemistry | Piperidines - administration & dosage | Piperidines - chemistry | Gastrointestinal Absorption | Administration, Oral | Curcumin - pharmacokinetics | Lipids - administration & dosage | Dronabinol - pharmacokinetics | Excipients - administration & dosage | Polyunsaturated Alkamides - administration & dosage | Animals | Lipids - pharmacokinetics | Stilbenes - pharmacokinetics | Alkaloids - administration & dosage | Nanoparticles - administration & dosage | Polyunsaturated Alkamides - pharmacokinetics | Dronabinol - administration & dosage | Dronabinol - chemistry | Alkaloids - chemistry
Journal Article
Journal Article
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 153 - 157
Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs. We examined... 
pharmacokinetics | dipeptidyl peptidase-4 inhibitor | glucagon-like peptide-1 receptor agonist | target molecular binding occupancy | pharmacodynamics | Dipeptidyl peptidase-4 inhibitor | Pharmacodynamics | Pharmacokinetics | Glucagon-like peptide-1 receptor agonist | Target molecular binding occupancy | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | PROMOTES SATIETY | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Peptides - pharmacokinetics | Nitriles - pharmacokinetics | Peptides - administration & dosage | Peptides - metabolism | Hypoglycemic Agents - administration & dosage | Pyrrolidines - metabolism | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Piperidines - metabolism | Pyrrolidines - pharmacokinetics | Adamantane - metabolism | Models, Molecular | Uracil - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Liraglutide - therapeutic use | Venoms - therapeutic use | Ligands | Venoms - metabolism | Sitagliptin Phosphate - pharmacokinetics | Venoms - pharmacokinetics | Nitriles - therapeutic use | Liraglutide - metabolism | Sitagliptin Phosphate - metabolism | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Pyrrolidines - therapeutic use | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Liraglutide - pharmacokinetics | Uracil - administration & dosage | Venoms - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Piperidines - pharmacokinetics | Adamantane - pharmacokinetics | Nitriles - metabolism | Reproducibility of Results | Diabetes Mellitus, Type 2 - blood | Algorithms | Piperidines - therapeutic use | Sitagliptin Phosphate - therapeutic use | Uracil - metabolism | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Uracil - pharmacokinetics | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - therapeutic use | Uracil - analogs & derivatives | Binding | Drugs | Effectiveness | Peptidase | Glucagon | Diabetes mellitus | Theoretical analysis | Low level | Receptors | Inhibitors | Nitric oxide | Occupancy | Hemoglobin | Agonists | Glucagon-like peptide 1 | Drug dosages
Journal Article
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 2, p. 349
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 06/2015, Volume 16, Issue 1, pp. 18 - 18
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
Journal Article
Clinical Nutrition, ISSN 0261-5614, 2015, Volume 34, Issue 6, pp. 1101 - 1108
Journal Article